Targeted Genetics Reports On Recombinant DNA Advisory Committee (RAC) Review Of Its Phase 1/2 Trial Of TgAAC94 For Rheumatoid Arthritis

Targeted Genetics Corporation (Nasdaq: TGEN) reported on the public hearing conducted by the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC), which reviewed the serious adverse event reported by Targeted Genetics surrounding the death of a patient participating in the Company’s Phase I/II trial of tgAAC94 for inflammatory arthritis. [click link for full article]

More: continued here

Filed under: Arthritis on September 20th, 2007